State Health Clinical and Scientific Centre for Colliers, Leninsk-Kuznetskiy, Russia
Russ. J. Immunol. 1997, December 15, 2 (3-4), 191-198.
It is known that in vitro treatment of blood mononuclear cells with IL-2 assures normalisation of cell functions. To facilitate immunocorrection peripheral blood mononuclear cells isolated from 7 septic patients were activated in vitro (extracorporally) with IL-2 and injected back to the patients’ blood. The injection of activated cells was performed simultaneously with basic therapy. Five patients had positive clinical dynamics, including lowered basal body temperature, stabilised blood pressure, and normalised biochemical and immunological parameters. The first signs of the convalescence could be observed by the day 1-2 after the therapy. However, two patients with septic shock and multiple organ failure exhibited no positive response to the therapy. Their health status declined continuously that led finally to their death. We concluded that the therapy with mononuclear cells activated with IL-2 was advantageous for treating initial stages of systemic superfluous inflammation if there were no septic shock and multiple organ failure.